0A6I Stock Overview
A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Soligenix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.41 |
| 52 Week High | US$31.81 |
| 52 Week Low | US$1.92 |
| Beta | 1.85 |
| 11 Month Change | -3.02% |
| 3 Month Change | -26.00% |
| 1 Year Change | -48.89% |
| 33 Year Change | -98.38% |
| 5 Year Change | n/a |
| Change since IPO | -99.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A6I | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -6.3% | 0.3% | 2.2% |
| 1Y | -48.9% | -18.3% | 8.0% |
Return vs Industry: 0A6I underperformed the UK Biotechs industry which returned -20.1% over the past year.
Return vs Market: 0A6I underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| 0A6I volatility | |
|---|---|
| 0A6I Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A6I's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A6I's weekly volatility has decreased from 55% to 15% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 14 | Christopher Schaber | www.soligenix.com |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease.
Soligenix, Inc. Fundamentals Summary
| 0A6I fundamental statistics | |
|---|---|
| Market cap | US$8.31m |
| Earnings (TTM) | -US$7.10m |
| Revenue (TTM) | US$364.18k |
22.8x
P/S Ratio-1.2x
P/E RatioIs 0A6I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A6I income statement (TTM) | |
|---|---|
| Revenue | US$364.18k |
| Cost of Revenue | US$340.92k |
| Gross Profit | US$23.27k |
| Other Expenses | US$7.12m |
| Earnings | -US$7.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.83 |
| Gross Margin | 6.39% |
| Net Profit Margin | -1,949.32% |
| Debt/Equity Ratio | 34.7% |
How did 0A6I perform over the long term?
See historical performance and comparison